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cies (4%), dispensing doctors (2%), drugsto-
res, and others (1%) [2].
Although pharmaceutical full-line wholesa-
lers still occupy a central position in the sup-
ply chain, major transformations took place 
in the European pharmaceutical distribution 
landscape, which led to the rise of new distri-
bution models in the recent years. On the one 
hand the turnover of direct sales from ma-
nufacturers has increased in some countries, 
and on the other hand – like in the UK – new 
distribution models like Direct to Pharmacy 
(DTP) or Reduced Wholesale Arrangements 
(RWA) have emerged (GIRP oral information 
2011, [3]). These structural changes lead to 
the fact that no pharmaceutical wholesaler 
in the UK carries the full range of medici-
INTRODUCTION
The distribution and supply of medicinal 
products have a direct impact on the quality 
of the health care system, because they are 
responsible for the immediate availability 
of medicinal products. In most European 
countries, the majority of medicinal pro-
ducts are distributed through the following 
distribution pathway: manufacturer → (pre-
wholesaler) → pharmaceutical full-line who-
lesaler → retail pharmacy → patient. Phar-
maceutical full-line wholesalers supply the 
majority (74%) of medicinal products sold in 
Europe [1]. Moreover, pharmaceutical full-li-
ne wholesalers distribute medicinal products 
to retail pharmacies (93%), hospital pharma-
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ABSTRACT
OBJECTIVES: The aim of the study was to draw a comprehensive picture of the pharmaceutical wholesale sector, outlining 
its socio-economic importance compared to different distribution systems such as short-line wholesaling, direct sales from 
manufacturers, Reduced Wholesale Arrangements (RWA) and Direct to Pharmacy (DTP) arrangements. Its role is consi-
dered from an economic, effectiveness and, most importantly, a public health viewpoint with qualitative and quantitative 
methods, focusing on France, Germany, Italy, the Netherlands, Spain and the UK.
METHODS: First, data has been sourced from annual GIRP and IMS-Health statistics; second, a systematic literature 
research verified the empirical findings; third, an online-questionnaire was directed to pharmacies. Further data have been 
sourced from a questionnaire, addressing GIRP-full-member associations and wholesale companies (return rate 86%).
RESULTS: On a weighted average, pharmaceutical full-line wholesalers in the observed countries alone pre-finance € 10.2 
bn over a period of 41 days the entire medicine-market and secure the cash-flow of the social-insurers (Germany: € 2.60 
bn for 38 days; Italy: € 2.27 bn for 68 days; the UK: € 1.48 bn for 36 days; France: € 1.28 bn for 22 days; Spain: € 969.76 
m for 27 days; the Netherlands: € 399.09 m for 30 days on average). On average, pharmaceutical full-line wholesalers are 
bundling products of 18.28 manufacturers per delivery. The process costs would increase by € 164,922.43 to € 171,510.06 
per year, if there were no pharmaceutical full-line wholesalers. These additional costs would have to be paid by manufac-
turers, pharmacies and finally by patients. Regarding the satisfaction with different distribution models, the results of the 
online-questionnaire show that pharmacists in the observed countries are very satisfied with the distribution through their 
pharmaceutical full-line wholesalers.
CONCLUSIONS: The study showed that pharmaceutical full-line wholesalers have an important and unique position in 
the pharmaceutical supply chain. Special functions like the pre-financing of the entire medicinal product market, or the 
guarantee of the continuous supply of all medicinal products verify these findings.
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nal products [4]. After the introduction of 
the first Direct to Pharmacy arrangement by 
Pfizer in 2007, experts were concerned about 
limited supplies to pharmacies, reduced ser-
vice levels (pharmacies to patients), reduced 
margins but increased distribution costs [5].
Considering the recent transformations, this 
study aimed at analyzing the structures, cha-
racteristics, efficiency and performance of the 
different distribution systems, such as phar-
maceutical full-line wholesaling, pharmaceu-
tical short-line wholesaling, direct sales from 
manufacturers, RWA and DTP arrangements. 
To reach this aim and in order to compare 
the different distribution systems, core indi-
cators such as market share, product range, 
pre-financing, satisfaction with the distribu-
tion systems in use, delivery time as well as 
the impact on process costs, if there were no 
pharmaceutical full-line wholesalers, were 
calculated and respectively collected.
The analysis particularly focused on the role 
of pharmaceutical full-line wholesalers as the 
main pharmaceutical suppliers. This position 
is being considered from an economic, effec-
tiveness and a public health viewpoint [4].
MATERIALS AND METHODS
To analyze the impact of different pharma-
ceutical distribution systems on the access to 
pharmaceutical products, primary and secon-
dary sources were used to obtain the neces-
sary data.
Study design
The study considers the above-described core 
indicators of the six biggest European phar-
maceutical markets: France, Germany, Italy, 
the Netherlands, Spain and the United King-
dom (UK).
To gain up-to-date information, the following 
study design was applied:
 - Statistical and qualitative data were pro-
vided by the European Association of 
Pharmaceutical Full-line Wholesalers 
(GIRP). Against this context GIRP’s an-
nual report, statistical information gathe-
red through GIRP’s member association 
as well as IMS Health data were used in 
this study.
 - To verify the data and to gain further in-
formation about the difference in the time 
effort for ordering medicinal products, a 
systematic literature research was con-
ducted.
 - An online questionnaire was developed, 
addressing pharmacists of five out of 
the six European major markets (Fran-
ce, Germany, the Netherlands, Spain and 
the UK; due to the lack of response from 
Italian pharmacists, this country has been 
excluded from analysis).
 - To obtain detailed information about the 
core indicators pre-financing and product 
range of pharmaceutical full-line whole-
salers, an additional questionnaire – ad-
dressing GIRP full-member associations 
and direct-member companies – was de-
signed. This information was sent elec-
tronically. Over a period of two months 
(May to June 2011) a return rate of 86% 
was achieved.
Market share
The turnover expressed in volumes repre-
sents the market share of wholesalers (full-
line and short-line), direct sales from manu-
facturers, DTP and RWA. The figures are 
based on data from IMS health and illustrate 
the retail market (Figure 1).
Pre-financing
The calculation of the pre-financing is ba-
sed on the Net Working Capital approach. 
According to this, the Net Working Capital 
Days are calculated as the sum of Days Sa-
les Outstanding (DSO – capital commitment 
from accounts receivable) and Days Invento-
ry Outstanding (DIO – capital commitment 
from stock) minus Days Payable Outstanding 
(DPO – pre-financing from manufacturers) 
[6].
In the course of the wholesalers’ survey core 
indicators like inventory turnover (DIO), 
DSO and DPO were collected to calculate the 
amount of pre-financing.
Pharmacists’ questionnaire
The aim of the online questionnaire was to 
evaluate the pharmacists’ satisfaction with the 
different pharmaceutical distribution systems 
and to detect potential concerns associated 
with these systems. Furthermore, additional 
core indicators such as delivery time of the 
different distribution systems as well as the 
number of manufacturers whose products are 
pooled in one order from one pharmaceutical 
full-line wholesaler were collected. In the pe-
riod between March and October 2011, 473 
pharmacists (66 in France, 100 in Germany, 
89 in the Netherlands, 124 in Spain and 94 in 
the UK) answered the questionnaire.
The results illustrate a trend and were 
analyzed with the software PASW (Predicti-
ve Analysis Software).
Process costs
Process costs were calculated based on the 
findings of a study conducted by the Institut 
für Pharmakoökonomie und Arzneimittello-
gistik (IPAM) (for detailed information ple-
ase see original source) [7].
The findings of the study showed that all ne-
cessary process steps are carried out by phar-
macy assistants. Therefore, national gross 
salaries per minute for pharmacy assistants 
were calculated and multiplied with the re-
corded time effort caused per order from 
pharmaceutical full-line wholesalers, respec-
France 2007
66%
34%
France 2010
63%
37%
Germany 2007
81%
19%
Germany 2010
84%
16%
Italy 2007
84%
16%
Italy 2010
88%
12%
the Netherlands 2007
92%
8%
92%
8%
the Netherlands 2010
Spain 2007
90%
10%
Spain 2010
96%
4%
the UK 2007
91%
3%
3%
4%
the UK 2010
73%
2%
15%
10%
Pharmaceutical wholesalers
Direct sales from manufacturers
DTP (Direct-To-Pharmacy)
RWA (Reduced Wholesale Arrangement) 
Figure 1. Turnover (units) by distribution channel – retail market France, Germany, Italy, the Netherlands, Spain, the UK, 2011 
[Source: Authors’ own calculation based on BG Pharma written information 2011, GIRP data 2007-2010, IMS health 2007-2011, 
CSRP written information 2011]
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signed. This information was sent elec-
tronically. Over a period of two months 
(May to June 2011) a return rate of 86% 
was achieved.
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89 in the Netherlands, 124 in Spain and 94 in 
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The results illustrate a trend and were 
analyzed with the software PASW (Predicti-
ve Analysis Software).
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tively from direct sales from manufacturers. 
The salary information was obtained from 
official statistical sources (Istat oral informa-
tion, 2001) [8-12].
The calculations are based on the assumptions 
of the Institut für Handelsforschung (IfH) 
[13].
To compare the impact on process costs per 
pharmacy and year of pharmaceutical full-
line wholesalers and direct sales from ma-
nufacturers, the calculation is based on the 
following data and assumptions:
 - The delivery frequency per day derived 
from the records of GIRP’s national as-
sociation members. The calculation of 
the deliveries per year is based on the 
assumption that pharmacies are supplied 
six times per week – 52 weeks per year 
– by their pharmaceutical full-line who-
lesalers.
 - Pharmaceutical full-line wholesalers pool 
numerous medicinal products from diffe-
rent manufacturers per order. Data from 
the pharmacists’ questionnaires were 
used to gain this information for each 
market. The process costs of a delivery 
from one manufacturer were multiplied 
by the number of different manufacturers 
pooled per wholesale order to compen-
sate the costs and to compare it with the 
costs per order from pharmaceutical full-
line wholesalers. To calculate the impact 
on the process costs of the direct sales 
from manufacturers, the process costs 
were multiplied amounting to 25%, 50% 
or 100% of wholesale deliveries per year.
RESULTS
The key European markets in our study are 
multichannel systems with full-line whole-
saling, short-line wholesaling and direct sa-
les [14]. However, in the recent years, new 
distribution models have emerged, like DTP 
and RWA in the UK, where pharmaceutical 
full-line wholesalers are no longer operating 
as a one stop shop [15]. In the DTP distri-
bution model pharmaceutical manufacturers 
deliver their medicinal products directly to 
the pharmacies through one or more logistic 
service providers. So far, only pharmaceuti-
cal full-line wholesalers operate as logistic 
service providers, whereas in the RWA, phar-
maceutical manufacturers use only a small 
number of selected wholesalers to distribute 
medicinal products [15].
Due to the fact that neither European nor na-
tional legislation offers clear definitions or 
classifications of the operators in the distribu-
tion chain, several national authorities grant a 
high number of distribution licenses resulting 
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in the fact that a diverse range of different 
operators are active in the market, even in 
markets where their activities are theoretical-
ly prohibited, which is the case in France and 
Spain. Due to a lack of control, it is possible 
that such distributors are still operating in the 
market [16]. Table I gives an overview of key 
features of the pharmaceutical distribution 
systems in the key markets observed.
In the observed six countries, 176 wholesale 
companies (21 of them on a national basis) 
generated an enormous turnover of € 91 bn. 
These companies are holding 730 operating 
sites, guaranteeing the continuous supply of 
104,300 dispensing points for the 332 million 
citizens. Furthermore, pharmaceutical full-
line wholesalers are holding 52,773 items on 
stock on average. Additionally, pharmaceuti-
cal full-line wholesalers in the six observed 
countries guarantee a delivery within 2.66 
hours, 15.88 times per week on average 
[2,17].
Market share
Due to the growing importance of alternative 
distribution systems as well as the increase 
of direct sales in many other countries and 
new regulations curbing pharmaceutical ex-
penditure, the turnover of the wholesale sec-
tor has been negatively affected by reduced 
margins following health care reforms and/or 
austerity measures. Furthermore, the increa-
sing number of patents expiring has led to a 
growing number of cheaper products [15].
The change in the pharmaceutical portfolios 
is another important factor, influencing the 
market growth rate of the pharmaceutical 
France Germany Italy The Netherlands Spain The UK
Type of distribution Multichannel Multichannel Multichannel Multichannel Multichannel Multichannel
Distribution through Full-line ws
Short-line ws*
Direct sales
Full-line ws
Short-line ws
Direct sales
Full-line ws
Direct sales
Full-line ws
Short-line ws
Direct sales
Full-line ws
Short-line ws*
Direct sales
Full-line ws**
Short-line ws
Direct sales
DTP, RWA
Wholesale licenses 25 4,000 650 300 300 1,675
Regional full-line 
wholesalers
3 8 83 0 55 6
National full-line 
wholesalers
3 5 2 5 3 3
National PSOs Yes Yes Yes No Yes No
Wholesalers deliver to 
hospital
No No No Yes Yes Yes
Ø deliveries/day 2 3.3 3 1 3 2
Table I. Overview of key features of the pharmaceutical distribution systems in France, Germany, Italy, the Netherlands, Spain, the 
UK, 2011 [4]
* Theoretically, there are no pharmaceutical short-line wholesalers in France and Spain because their activities are prohibited in these countries. Due 
to a lack of clear definitions in national legislations a wide and diverse range of different operators is active in the supply chain
** Currently there are no wholesalers in the UK carrying the full range of products
DTP = Direct to Pharmacy; PSO = Public Service Obligation; RWA = Reduced Wholesale Arrangements; ws = wholesaler
wholesale model versus the direct sales mo-
del. According to the public service function, 
pharmaceutical full-line wholesalers have 
to handle all medicinal products, whereas 
pharmaceutical short-liners and direct sales 
distributors have the option to predominan-
tly distribute specialty, high volume and high 
margin products (“cherry picking”) [15,18].
Pre-financing
Pharmaceutical full-line wholesalers are the 
only ones who offer a pre-financing function 
toward manufacturers and pharmacies. By 
purchasing medicinal products from ma-
nufacturers, pharmaceutical full-line who-
lesalers acquire the ownership over these 
products. This ownership is then passed on 
to pharmacies when medicinal products are 
delivered. Pharmaceutical full-line wholesa-
lers also undertake a significant contribution 
to hedge the cash flow in the social security 
system, as pharmacies frequently delay (of-
ten after reimbursement from the Statutory 
Health Insurance (SHI)) the payments. Mo-
reover, in the context of warehousing, the 
coverage of incurred capital commitment and 
risks, such as spoilage, breakage and loss is 
guaranteed [13].
Nearly the entire medicinal product market is 
pre-financed by pharmaceutical wholesalers 
and can be expressed in terms of working ca-
pital. The calculation of the pre-financing 
was based on a national pharmaceutical full-
line wholesale basis, as they can claim to be 
representative for all wholesalers in the mar-
kets observed. On a weighted average, phar-
maceutical full-line wholesaler in France, 
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observed were satisfied. The satisfaction ran-
ged from 58% in Spain to 12% in UK. The 
majority (80%) of the pharmacists in the UK 
were unsatisfied with this kind of distribution 
system. The satisfaction with the delivery 
time ranged from 41% in Germany and the 
Netherlands to 15% in the UK; whereas the 
dissatisfaction ranged from 76% in UK to 9% 
in the Netherlands.
According to the questionnaire findings, 
the respondent pharmacists were concerned 
about the ability to provide service to patients 
(Germany, UK, Spain) as well as increasing 
stock and order effort (Germany, UK) when 
ordering their medicinal products from direct 
sales from manufacturer. Regarding the sa-
tisfaction with the distribution through DTP 
and the delivery time offered, the majority of 
the pharmacists in the UK were unsatisfied. 
More than half (59%) of the respondent phar-
macists in UK were not satisfied with the de-
livery time through RWA (Table II).
Germany, Italy, the Netherlands, Spain and 
the UK alone pre-finance on average € 10.2 
bn over a period of 41 days. In total, this sum 
is pre-financed approximately nine times per 
year (Figure 2).
The country specific results revealed that in 
Germany, pharmaceutical wholesalers pre-fi-
nance € 2.60 bn for 38 days, in Italy € 2.27 bn 
for 68 days, in the UK € 1.48 bn for 36 days, 
in France € 1.28 bn for 22 days, in Spain € 
969.76 m for 27 days and in the Netherlands 
€ 399.09 m for 30 days on average (Figure 3).
Pharmacists’ satisfaction
With regard to the distribution system, the 
results revealed that in most of the observed 
countries, more than three quarters of the re-
spondent pharmacists were satisfied with the 
distribution through pharmaceutical full-line 
wholesalers. The satisfaction of the participa-
ting pharmacists with this type of distribution 
system ranged from 99% in Spain to 72% in 
the UK. With regard to the delivery time offe-
red by pharmaceutical full-line wholesalers, 
the satisfaction ranged from 97% in Spain 
to 76% in UK. With the distribution throu-
gh the pharmaceutical short-line wholesalers, 
more than half (63%) of the German phar-
macists were satisfied, whereas only 50% of 
the Dutch participants showed satisfaction. 
Regarding the delivery time offered by phar-
maceutical short-line wholesalers, a slight 
majority (56%) of the German pharmacists 
were satisfied, while less than half (44%) 
of the respondents in the Netherlands repor-
ted their satisfaction with the delivery time 
of pharmaceutical short-line wholesalers as 
“neutral”; 39% were satisfied, and 17% sho-
wed dissatisfaction.
The results of the satisfaction with the di-
stribution through direct sales from manu-
factures revealed that less than half of the 
respondents in four out of the five countries 
Wholesaler 
purchase from 
Manufacturer
Receipt
Payment by 
Wholesaler
Pre-financing 
manufacturer
Order-Delivery 
to pharmacies 
and billing
Pre-financing 
wholesaler
Expected receipt of 
payment from social 
insurance funds
Actual 
receipt of 
Payment
t
Manufactures Wholesalers Pharmacies
Working Capital = € 10.2 bn for 41 days
Figure 2. Pre-financing in bn € in France, Germany, Italy, the Netherlands, Spain, the UK, 2010 [4]
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Figure 3. Pre-financing in million € in France (FR), Germany (DE), Italy (IT), the 
Netherlands (NL), Spain (ES), the UK, 2010 [4]
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With the introduction of DTP in 2007, ex-
perts predicted their concerns about quotas, 
which currently lead to a lack of supply, lack 
of availability of medicinal products and 
stock problems. As a consequence, pharma-
cists are more and more unable to meet the 
patients’ needs and to provide good service 
[4,5].
As the Netherlands is – compared to its nei-
ghbour countries – a low-price country with a 
high amount of exports, an increasing pro-
blem of out of stocks (availability of medici-
nal products) occurs [4,19]. 
In Spain, pharmacists complained about 
shortages of medicinal products and as a re-
sult about supply problems when ordering 
products via direct sales from manufacturers 
as well as long delivery times. Therefore, 
pharmacists face problems to provide servi-
ce for patients as usual [4]. Pharmacists in 
Germany criticized order conditions offered 
by direct sales from manufacturers. General-
ly, pharmacists complained about the decre-
ase in discount rates. 13% of the pharmacists 
believe that these decreased discounts would 
lead to financial problems. The reason may 
lie in the recent reforms of the healthca-
re system (GKV-ÄndG, AMNOG, GMG) 
[4,20,21].
Satisfaction with the distribution system (%) Satisfaction with the delivery time (%)
Satisfied Neutral Unsatisfied Satisfied Neutral Unsatisfied
Pharmaceutical full-line wholesalers
France 90.90 6.10 3.00 95.50 4.50 -
Germany 78.70 14.60 6.70 92.10 7.90 -
The Netherlands 75.30 20.20 4.50 86.50 12.40 1.10
Spain 99.20 0.80 - 96.70 1.60 1.60
The UK 71.86 12.67 15.52 75.87 12.64 11.54
Pharmaceutical short-line wholesalers
Germany 62.50 37.50 - 56.30 25.00 18.80
The Netherlands 50.00 33.30 16.70 38.90 44.40 16.70
Direct sales from manufacturers
France 51.80 42.90 5.40 32.10 55.40 12.50
Germany 49.20 39.00 11.90 40.70 47.50 11.90
The Netherlands 50.00 36.40 13.60 40.90 50.00 9.10
Spain 57.70 41.00 1.30 21.80 43.60 34.60
The UK 11.90 8.50 79.70 15.30 8.50 76.30
DTP (Direct to Pharmacy)
The UK 8.00 2.30 89.70 9.20 14.90 75.90
RWA (Reduced Wholesale Arrangements)
The UK 6.20 3.10 90.80 13.80 27.70 58.50
Table II. Satisfaction with the distribution system and delivery time per country and distribution system in France, Germany, the 
Netherlands, Spain, the UK, 2011 [Source: Authors’ own calculation based on questionnaire data 2011]
* Due to the fact that no wholesaler in the UK stocks all medicinal products the results related to pharmaceutical full-line and short-line wholesalers 
have been pooled together and collectively assessed as ‘wholesalers’.
Delivery time
In order to use medicinal products for therapy, 
it is necessary that they are available in time. 
According to the pharmacists’ questionnaire 
findings, the delivery time of the different di-
stribution systems shows the following picture:
 - On average, a pharmaceutical full-line 
wholesaler supplies a pharmacy within 
a delivery time of 4.53 hours (count-
ry specific results: France = 4.80 hours; 
Germany = 2.85 hours; the Netherlands = 
16.35 hours; Spain = 4.15 hours; the UK 
= 5.70 hours).
 - Pharmacists are supplied within an ave-
rage delivery time of 14.57 hours by 
their pharmaceutical short-line whole-
saler (country specific results: Germany 
= 15.90 hours; the Netherlands = 21.50 
hours).
 - Manufacturers (direct sales) distribute 
their medicinal products within a delive-
ry time of 53.41 hours (country specific 
results: France = 41.67 hours; Germany 
= 26.00 hours; the Netherlands = 32.55 
hours; Spain = 97.63 hours; the UK = 
48.57 hours).
 - In the UK an average pharmacy is sup-
plied within 11.56 hours by RWA, respec-
tively within 17.57 hours by DTP [4].
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These figures represent the collected and the 
weighted data respectively from the phar-
macists’ questionnaires. The reason why the 
reported delivery time of the pharmaceuti-
cal full-line wholesalers (2.66 hours) differs 
from the perceived one from pharmacists 
(4.53 hours) is the fact that the night-time, as 
well as Sundays, were excluded from the re-
ported delivery time [4].
Impact on process costs
The average individual process steps in phar-
macies include determining of order demand, 
transmission of order, receiving and storage 
of delivery, checking the delivery note, and 
invoice [7,13]. Based on these findings and 
on the results from the questionnaires, the 
process costs as well as the impact on process 
costs were calculated. On a weighted avera-
ge, pharmaceutical full-line wholesalers are 
pooling products of 18.28 manufacturers per 
delivery. The cost difference of one delivery 
from a manufacturer is € 3.38 compared to 
one delivery from one pharmaceutical full-
line wholesaler, whereas the cost difference 
based on 18.28 deliveries from different ma-
nufacturers is € 199.71, compared to one de-
livery from a pharmaceutical full-line whole-
saler, where products of 18.28 manufacturers 
are bundled. According to the reported deli-
veries per week of the GIRP member organi-
zation, pharmacies are supplied on average 
15.88 times per week, including deliveries to 
rural areas. Taking the average deliveries per 
week into account, the process costs accruing 
to pharmacies reveal that without pooling, 
the cost will increase from € 6,587.63 to € 
42,877.51 per year, resulting in a cost diffe-
rence of € 36,289.88, if 25% of wholesale 
deliveries/week were delivered by the manu-
facturers directly. Direct distribution with 
weekly deliveries amounting to 50% of who-
lesale deliveries would increase the process 
costs by € 79,167.40 per year. Strictly spea-
king, with the same delivery frequency, the 
process costs would increase by € 164,922.43 
to € 171,510.06 per year, if there were no 
pharmaceutical full-line wholesalers.
Table III shows the results of the impact on 
process costs per pharmacy, country and year. 
If the pharmacy is supplied only by whole-
salers, the process costs per year are the hi-
ghest with € 8,049.71 in Germany, compared 
to the Netherlands with € 2,670.94. Without 
pooling, the costs are highest in Spain with 
€ 61,657.62 and lowest in the Netherlands 
with € 13,780.25, if 25% of wholesale de-
liveries per week are delivered by the ma-
nufacturers directly. Direct distribution with 
weekly deliveries amounting to 50% of who-
lesale deliveries, result in process costs of € 
123,315.25 in Spain and of € 27,560.50 in 
the Netherlands. Assuming the same deli-
very frequency, the process costs are the hi-
ghest in Spain with € 246,630.49 and lowest 
in the Netherlands with € 55,121.01, if there 
were no pharmaceutical full-line wholesa-
lers. These additional costs would have to be 
paid by manufacturers, pharmacies and final-
ly by the patients
Currently, the pharmaceutical sector is torn 
between rapid and radical transformations, 
such as austerity measures, price decreases, 
margin cuts and the rise of new alternative 
distribution models taking place. However, 
for the pharmaceutical industry and pharma-
cies and indirectly for patients, the pharma-
ceutical wholesale sector has proven to be a 
reliable partner. Additionally, pharmaceutical 
full-line wholesalers have proven to be vital 
and reliable partners for policy makers, trying 
to find strategies and solutions for the current 
and future challenges in the European health 
care sector together with policy makers, all 
other stakeholders involved, the representati-
ves of health funds, and patients [14].
Wholesale deliveries 
(~ 16 deliveries/week)  
(€)
Manufacturers 
amounting to 25% of 
wholesale deliveries  
(€)
Manufacturers 
amounting to 50% of 
wholesale deliveries  
(€)
Manufacturers 
amounting to 100% of 
wholesale deliveries  
(€)
France 4,430.36 21,343.27 42,686.53 85,373.06
Germany 8,049.71 52,795.11 105,590.23 211,180.46
Italy 8,022.95 57,133.12 114,266.23 228,532.47
The Netherlands 2,670.94 13,780.25 27,560.50 55,121.01
Spain 7,428.83 61,657.62 123,315.25 246,630.49
The UK 5,107.58 29,115.92 58,231.83 116,463.67
Weighted average 6,587.63 42,877.51 85,755.03 171,510.06
Table III. Scenario: Impact on process costs per pharmacy and year (pharmaceutical full-line wholesalers vs. direct sales from 
manufacturers) in France, Germany, Italy, the Netherlands, Spain, the UK, 2011 [Source: Authors’ own calculation based on Bureau 
of Labor Statistics 2010, Center for Healthcare supply chain research 2007, De Grip et al. [8], Instituto Nacional de Estadistica 2008, 
Istat 2009, pharmacists questionnaire, OECD 2008, Statistisches Bundesamt Deutschland 2010]
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DISCUSSION
This study, in our knowledge the first provi-
ding a systematic overview on the impact of 
different distribution systems on the access to 
pharmaceutical products in the key Europe-
an markets, showed that the pharmaceutical 
full-line wholesalers have an important and 
unique position in the pharmaceutical sup-
ply chain. In the observed countries alone, 
pharmaceutical full-line wholesalers pre-
finance on average € 10.2 bn over a period 
of 41 days. Moreover, they guarantee the 
continuous supply of all medicinal products. 
With the delivery frequency (15.88 times per 
week), the process costs would increase by € 
164,922.43 to € 171,510.06 per year, if there 
were no pharmaceutical full-line wholesa-
lers. These findings could be attributed to the 
consolidated view of the satisfaction of the 
pharmacists in the observed countries, indi-
cating that pharmacists are very satisfied with 
the distribution through their pharmaceutical 
full-line wholesalers.
This study has the following limitations: 
calculations on the impact of process costs 
build up on the assumption that each ma-
nufacturer distribute to each pharmacy, lea-
ding to a very high number of transactions. 
In the case, if more and more manufacturers 
would start to deliver directly, some sort of 
bundling institution (wholesaler or logistics 
service provider) would establish. Therefore, 
it is really difficult to compare today’s who-
lesale system with a (theoretical) pure direct 
delivery scheme, as a pure direct delivery sy-
stem most probably cannot exist. Moreover, 
it has to be considered that the findings of 
the pharmacists’ survey are a snap shot of the 
individual’s opinion at a particular moment 
in time. In addition, the results illustrate a 
trend.
Other distributors, such as short-line whole-
salers or manufacturers through direct sales, 
carry only a limited product range (their own 
products) of mostly fast turning, high margin 
lines and typically do not offer added value 
services to their customers. Nevertheless, by 
generating information, direct sales from ma-
nufacturers have gained momentum in recent 
years.
The share of innovative medicinal products 
of the product portfolio is decreasing, due to 
the expiration of patents of blockbuster medi-
cinal products. This fact leads to a degression 
of margins and in the long run to higher pri-
ces for patients (e.g. fee for service). The stu-
dy has proven that other forms of distribution 
lead to higher costs, would have to be paid 
by manufacturers, pharmacies and finally by 
patients.
If pharmaceutical full-line wholesalers cease 
to exist, the continuous supply of all medici-
nal products from one single source and in 
the shortest possible time would no longer be 
guaranteed. Additionally, without the servi-
ces provided by pharmaceutical wholesalers 
that create added value for their customers, 
they would not be able to focus exclusively 
on their core business (pharmaceutical manu-
facturers on the development, production and 
marketing of medicinal products; pharmacies 
on the dispensing of medicines and to advice 
patients; doctors on diagnosing and prescri-
bing therapies to their patients).
Against this background, it can be assumed 
that pharmaceutical full-line wholesalers will 
also be engaged more and more in the role of 
health service providers, which is already the 
case in the UK and in the Netherlands, where 
they have become partners of Health Service 
Centres.
In conclusion, the present study showed that 
no other distribution model is in the posi-
tion to keep up with pharmaceutical full-line 
wholesalers, because they help to reduce 
transaction costs and secure a safe, rapid and 
continuous supply of medicinal products. 
Moreover, they help generate value along the 
pharmaceutical supply chain by providing 
complementary services to their supply chain 
partners.
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